Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasritamig plus docetaxel vs docetaxel in metastatic castration-resistant prostate cancer
ChiCTR2600117391Phase 3Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of pasritamig in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Radiographic Progression-Free Survival (rPFS). Planned start Jan 2026; status: not yet recruiting.
02
Drugs
pasritamig
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on ChiCTR2600117391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117391.